Karuna Therapeutics, Inc., A Bristol Myers Squibb Company
Clinical trials sponsored by Karuna Therapeutics, Inc., A Bristol Myers Squibb Company, explained in plain language.
-
New drug trial aims to tame terrifying hallucinations in Alzheimer's patients
Disease control Recruiting nowThis study is testing whether a drug called KarXT can help prevent the return of distressing psychosis symptoms—like hallucinations and delusions—in people with Alzheimer's disease. It will involve about 410 participants aged 55-90 who have these symptoms. Over 38 weeks, research…
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for teens: Long-Term safety testing of mental health treatment
Disease control Recruiting nowThis study aims to understand the long-term safety of KarXT for teenagers with schizophrenia and children with autism-related irritability. It follows 400 young participants who have already completed earlier studies with these medications. Researchers will monitor side effects a…
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Year-Long safety check for promising new schizophrenia treatment
Disease control Recruiting nowThis study aims to check the long-term safety of adding a new drug called KarXT to the current antipsychotic medications of adults with schizophrenia. It will follow about 280 people for one year to see how well they tolerate the combined treatment. The goal is to see if this add…
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC